Search research articles
Contact Us
Filters
Showing results (191-200 of 212) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2021
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Alexander N Shoushtari, Walid K Chatila, Arshi Arora, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Science Immunology
|
July 28, 2023
Clonally expanded CD38<sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
Runci Wang, Anvita Singaraju, Kathryne E Marks, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature Communications
|
July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
Nature Genetics
|
January 5, 2021
The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero, Mark Lee, Douglas Hoen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Nature Communications
|
February 2, 2021
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Cristina Valero, Mark Lee, Douglas Hoen, et al.
Nature
|
October 8, 2015
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
Thomas Wiesner, William Lee, Anna C Obenauf, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 212) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2021
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Alexander N Shoushtari, Walid K Chatila, Arshi Arora, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Science Immunology
|
July 28, 2023
Clonally expanded CD38<sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
Runci Wang, Anvita Singaraju, Kathryne E Marks, et al.
Journal for Immunotherapy of Cancer
|
April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Nature Communications
|
July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
Nature Genetics
|
January 5, 2021
The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero, Mark Lee, Douglas Hoen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Nature Communications
|
February 2, 2021
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Cristina Valero, Mark Lee, Douglas Hoen, et al.
Nature
|
October 8, 2015
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
Thomas Wiesner, William Lee, Anna C Obenauf, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 22